Peter J Whitehouse

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12163260/publications.pdf

Version: 2024-02-01

60 papers 7,008 citations

147801 31 h-index 55 g-index

60 all docs 60 does citations

times ranked

60

4454 citing authors

#	Article	IF	CITATIONS
1	Ethical issues in early diagnosis and prevention of Alzheimer disease. Dialogues in Clinical Neuroscience, 2019, 21, 101-108.	3.7	20
2	A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genetics in Medicine, 2018, 20, 132-141.	2.4	36
3	Ekosustav bioetike. Jahr, 2017, 8, 227-243.	0.5	4
4	Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease. Annals of Internal Medicine, 2016, 164, 155.	3.9	34
5	A Tale of Two Reports: What Recent Publications from the Alzheimer's Association and Institute of Medicine say about the State of the Field. Journal of Alzheimer's Disease, 2015, 49, 21-25.	2.6	8
6	A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1222-1230.	0.8	28
7	Public Justice. International Journal of Aging and Human Development, 2014, 80, 95-98.	1.6	1
8	InterWell: an integrated school-based primary care model. London Journal of Primary Care, 2013, 5, 106-110.	0.9	8
9	InterWell: an integrated school-based primary care model. London Journal of Primary Care, 2013, 5, 83-7.	0.9	3
10	Describing the Dying Days of "Alzheimer's Disease― Journal of Alzheimer's Disease, 2011, 24, 11-13.	2.6	15
10	Describing the Dying Days of "Alzheimer's Disease― Journal of Alzheimer's Disease, 2011, 24, 11-13. The Future of Dementia: A Case of Hardening of the Categories. American Journal of Geriatric Psychiatry, 2010, 18, 755-758.	2.6	0
	The Future of Dementia: A Case of Hardening of the Categories. American Journal of Geriatric		
11	The Future of Dementia: A Case of Hardening of the Categories. American Journal of Geriatric Psychiatry, 2010, 18, 755-758.	1.2	0
11 12	The Future of Dementia: A Case of Hardening of the Categories. American Journal of Geriatric Psychiatry, 2010, 18, 755-758. Changing perspectives regarding late-life dementia. Nature Reviews Neurology, 2009, 5, 649-658. Disclosure of <i>APOE </i> Fish of Alzheimer's Disease. New England Journal of Medicine,	1.2	0 259
11 12 13	The Future of Dementia: A Case of Hardening of the Categories. American Journal of Geriatric Psychiatry, 2010, 18, 755-758. Changing perspectives regarding late-life dementia. Nature Reviews Neurology, 2009, 5, 649-658. Disclosure of <i>APOE </i> Genotype for Risk of Alzheimer's Disease. New England Journal of Medicine, 2009, 361, 245-254. National Institute of Health and Clinical Excellence Decision Processes Supported by UK High Court: The Debate about the Value of Alzheimer's Disease Drugs Continues. Journal of Alzheimer's Disease,	1.2 10.1 27.0	0 259 490
11 12 13	The Future of Dementia: A Case of Hardening of the Categories. American Journal of Geriatric Psychiatry, 2010, 18, 755-758. Changing perspectives regarding late-life dementia. Nature Reviews Neurology, 2009, 5, 649-658. Disclosure of (i) APOE (i) Genotype for Risk of Alzheimer's Disease. New England Journal of Medicine, 2009, 361, 245-254. National Institute of Health and Clinical Excellence Decision Processes Supported by UK High Court: The Debate about the Value of Alzheimer's Disease Drugs Continues. Journal of Alzheimer's Disease, 2008, 13, 239-240. Involuntary emotional expressive disorder: A case for a deeper neuroethics. Neurotherapeutics, 2007,	1.2 10.1 27.0 2.6	0 259 490
11 12 13 14	The Future of Dementia: A Case of Hardening of the Categories. American Journal of Geriatric Psychiatry, 2010, 18, 755-758. Changing perspectives regarding late-life dementia. Nature Reviews Neurology, 2009, 5, 649-658. Disclosure of i> APOE / i> Genotype for Risk of Alzheimer's Disease. New England Journal of Medicine, 2009, 361, 245-254. National Institute of Health and Clinical Excellence Decision Processes Supported by UK High Court: The Debate about the Value of Alzheimer's Disease Drugs Continues. Journal of Alzheimer's Disease, 2008, 13, 239-240. Involuntary emotional expressive disorder: A case for a deeper neuroethics. Neurotherapeutics, 2007, 4, 560-567. Quality of life: The bridge from the cholinergic basal forebrain to cognitive science and bioethics.	1.2 10.1 27.0 2.6 4.4	0 259 490 0

#	Article	IF	Citations
19	Anthropological contributions to the understanding of age-related cognitive impairment. Lancet Neurology, The, 2005, 4, 320-326.	10.2	33
20	Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genetics in Medicine, 2004, 6, 197-203.	2.4	101
21	Paying attention to acetylcholine: the key to wisdom and quality of life?. Progress in Brain Research, 2004, 145, 311-317.	1.4	12
22	Regulatory aspects of mild cognitive impairment: toward a harmonized perspective. Dialogues in Clinical Neuroscience, 2004, 6, 409-414.	3.7	2
23	Reasons for Seeking Genetic Susceptibility Testing Among First-Degree Relatives of People With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2003, 17, 86-93.	1.3	82
24	Van Rensselaer Potter: An Intellectual Memoir. Cambridge Quarterly of Healthcare Ethics, 2002, 11, 331-334.	0.8	9
25	Managed Care and Complementary and Alternative Medicine: Lessons from the Past and Suggestions for the Future. Journal of Alternative and Complementary Medicine, 1999, 5, 1-2.	2.1	1
26	Progress in the Management of Alzheimer's Disease. Hospital Practice (1995), 1998, 33, 151-166.	1.0	5
27	Evaluation of Dementia. New England Journal of Medicine, 1996, 335, 330-336.	27.0	185
28	Fairhill Guidelines on Ethics of the Care of People With Alzheimer's Disease: A Clinical Summary*. Journal of the American Geriatrics Society, 1995, 43, 1423-1429.	2.6	108
29	Alteration of Phospholipase Câ€Î´ Protein Level and Specific Activity in Alzheimer's Disease. Journal of Neurochemistry, 1995, 64, 2629-2634.	3.9	25
30	Pharmacotherapy for Alzheimer's Disease. Clinics in Geriatric Medicine, 1994, 10, 339-350.	2.6	7
31	Aberrant Phosphoinositide Metabolism in Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1993, 695, 46-49.	3.8	8
32	A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease. New England Journal of Medicine, 1992, 327, 1253-1259.	27.0	627
33	Alzheimer's Disease: Relationship of Cognition and Behavior to Neurochemistry. International Psychogeriatrics, 1992, 4, 71-78.	1.0	9
34	Dementia: Nosology and Brain-Behavior Relationships. Dementia and Geriatric Cognitive Disorders, 1991, 2, 116-120.	1.5	0
35	Assessment of Behavioral and Affective Symptoms in Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 1990, 3, 21-30.	2.3	145
36	Parkinson's disease and Alzheimer's disease: New neurochemical parallels. Movement Disorders, 1989, 4, S57-S62.	3.9	10

#	Article	IF	Citations
37	Bilateral changes in neocortical [3H]pirenzepine and [3H]oxotremorine-M binding following unilateral lesions of the rat nucleus basalis magnocellularis: an autoradiographic study. Brain Research, 1989, 483, 367-372.	2.2	33
38	Alzheimer's Dementia: Performance on parallel forms of the Dementia Assessment Battery. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1989, 11, 899-912.	1.1	26
39	Abnormalities in Corticotropin-releasing Hormone (CRH) in Alzheimer's Disease and Other Human Disorders. Annals of the New York Academy of Sciences, 1987, 512, 237-247.	3.8	45
40	Muscarinic and nicotinic cholinergic binding sites in alzheimer's disease cerebral cortex. Brain Research, 1987, 436, 62-68.	2.2	145
41	Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease. Brain Research, 1987, 437, 355-359.	2.2	33
42	Immunohistochemical study of neurons containing corticotropin-releasing factor in Alzheimer's disease. Synapse, 1987, 1, 405-410.	1.2	66
43	Loss of pedunculopontine neurons in progressive supranuclear palsy. Annals of Neurology, 1987, 22, 18-25.	5.3	181
44	Aminergic systems in Alzheimer's disease and Parkinson's disease. Annals of Neurology, 1987, 22, 229-236.	5.3	230
45	Dysfunction and Death of Neurons in Human Degenerative Neurological Diseases and in Animal Models. Novartis Foundation Symposium, 1987, 126, 30-48.	1.1	9
46	Cellular pathology in Alzheimer's and Parkinson's diseases. Trends in Neurosciences, 1986, 9, 29-33.	8.6	67
47	Cholinergic receptors in aging and Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1986, 10, 665-676.	4.8	68
48	Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Research, 1986, 371, 146-151.	2.2	541
49	Primary Degenerative Dementia Without Alzheimer Pathology. Canadian Journal of Neurological Sciences, 1986, 13, 462-470.	0.5	69
50	The concept of subcortical and cortical dementia: Another look. Annals of Neurology, 1986, 19, 1-6.	5.3	195
51	Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature, 1986, 319, 593-595.	27.8	260
52	Molecular Approaches to Human Neurological Diseases and Their Animal Models. , 1986, , 171-180.		1
53	Neuropathological processes in Alzheimer's disease. Drug Development Research, 1985, 5, 59-68.	2.9	6
54	Neurotransmitter receptors in amyotrophic lateral sclerosis: Possible relationship to sparing of eye movements. Annals of Neurology, 1985, 17, 518-518.	5.3	9

#	Article	IF	CITATIONS
55	Neurotransmitter receptor alterations in Huntington's disease: Autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Annals of Neurology, 1985, 18, 202-210.	5.3	83
56	Abnormalities of the nucleus basalis in Down's syndrome. Annals of Neurology, 1985, 18, 310-313.	5.3	196
57	Corticotropin-Releasing Factor Receptors in Human Pituitary Gland: Autoradiographic Localization. Neuroendocrinology, 1985, 40, 419-422.	2.5	50
58	Basal forebrain neurons in the dementia of Parkinson disease. Annals of Neurology, 1983, 13, 243-248.	5. 3	527
59	Amyotrophic lateral sclerosis: Alterations in neurotransmitter receptors. Annals of Neurology, 1983, 14, 8-16.	5.3	151
60	Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology, 1981, 10, 122-126.	5.3	1,694